Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.
about
Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes.Kynurenines in the mammalian brain: when physiology meets pathologyEfficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an updateTargeted Deletion of Kynurenine 3-Monooxygenase in Mice: A NEW TOOL FOR STUDYING KYNURENINE PATHWAY METABOLISM IN PERIPHERY AND BRAINChronic Toxoplasma gondii in Nurr1-null heterozygous mice exacerbates elevated open field activityInflammation and the two-hit hypothesis of schizophrenia.Deficiency of schnurri-2, an MHC enhancer binding protein, induces mild chronic inflammation in the brain and confers molecular, neuronal, and behavioral phenotypes related to schizophrenia.Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.Abnormal white matter microstructure and increased extracellular free-water in the cingulum bundle associated with delusions in chronic schizophrenia.Evidence for an immune role on cognition in schizophrenia: a systematic reviewCortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia.Transcriptomic evidence for immaturity of the prefrontal cortex in patients with schizophrenia.Frontal-subcortical protein expression following prenatal exposure to maternal inflammation.Marked reduction of AKT1 expression and deregulation of AKT1-associated pathways in peripheral blood mononuclear cells of schizophrenia patients.Cingulum bundle diffusivity and delusions of reference in first episode and chronic schizophrenia.Network-assisted investigation of combined causal signals from genome-wide association studies in schizophreniaPaliperidone: the evidence of its therapeutic value in schizophrenia.Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onsetInfectious Agents are Associated with Psychiatric Diseases.Levels of S100B are raised in female patients with schizophrenia.Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity.Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders.Latent toxoplasmosis and humanElevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamineKynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantineImmature dentate gyrus: an endophenotype of neuropsychiatric disorders.Proteomic profiling in schizophrenia: enabling stratification for more effective treatment.Elevated cytokine expression in the orbitofrontal cortex of victims of suicidePsychiatric research: psychoproteomics, degradomics and systems biology.A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder.Serial mitogen-stimulated cytokine production from continuously ill patients with schizophrenia.Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER)Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy.Tryptophan as an evolutionarily conserved signal to brain serotonin: molecular evidence and psychiatric implications.Comparative immunogenetics of autism and schizophrenia.Neurosarcoidosis and the complexity in its differential diagnoses: a review.Blood test for schizophrenia.S100B and schizophrenia.
P2860
Q24631189-99CA6535-E6D0-4EAA-A236-B93C2168EB56Q27003296-10A4F7FE-3987-49EF-BDE9-600B9C207818Q28299995-6959C4F3-DAA2-4253-906F-88280324F032Q29306917-80F22DEA-809D-45A0-9924-57004FB8EE72Q30413968-FA4876AB-1E75-4292-819B-F6BD9DD714E8Q30422062-54D0AB87-1D26-4A77-97A6-C0A4C41A082FQ30453022-E041BFD3-2378-44DC-80FE-616057FB9CD1Q30544793-6E4ADB88-2E3D-4BD3-8194-E7D64E23976EQ31130094-70FE932F-74FD-459D-AFD2-231FB345E548Q33621692-05F1E132-E073-4E79-A7E0-96733E944696Q33707711-A9A7DD06-7CA6-4CD6-B7F9-5BA3FA29B97EQ33789078-8F1BA48B-69D5-4604-A81C-9D69062F7DEAQ33828632-B12ED6DF-9638-42C8-A86E-8A016768162BQ34185951-A18B2710-E3A3-4D5B-AD1A-F9D522092547Q34332635-C721C41F-444F-4958-ABFC-762B1A28FB04Q34335485-7DE372F4-8AB8-485C-8BE0-2B8FFD36215FQ34449894-2A012D94-E7BE-4EE8-B1F5-2D8B6B02F1F4Q34496393-7B2CFBC1-C5FE-4FD0-B011-B9075588ACC4Q34618873-048064DE-780B-4DF3-932B-748E4F2293F9Q34738782-900EDEA2-4D42-4E1C-BF7B-1E08D289A71AQ35390305-98D245F3-C404-478B-BB9E-1F5B74218C25Q36071533-37EF5003-0991-4629-A515-EE39F3D0D471Q36118835-3FBF47E3-6D9F-4DFE-A7C0-33073058007CQ36370599-03FE6605-CEB8-4F93-879A-21C956336350Q36579965-BFC42DE9-2F3A-4051-BE80-181BE9C099CFQ36755954-3735C12F-C81D-4E43-A644-D778A8982286Q36778677-3940093A-3DA2-4D94-A98E-16A4F7C9AD8DQ36960113-C93BA09C-ADEE-47A9-97B5-D06E3D204E11Q36998471-494369F4-036A-4131-978A-EC4F3DB447E2Q37032702-D5348203-F583-4428-9040-26D29E90FE54Q37157851-60AC067B-05C4-4498-9643-56138CB4E784Q37395509-2CA48404-3AB4-49DB-84CD-19B098EB0737Q37479996-40D82979-D13F-4FA8-A05A-3BA18952DA36Q37516094-01749C62-D179-4CA0-A7A9-8C5F568A0B97Q37546096-D09EB666-5AD0-4FD9-8A25-8FDD34179B38Q37634502-610085A4-A1DC-4265-B556-9CDFB35CFA80Q37886065-14ECD39D-1055-46DC-B15A-14818E7D99F8Q38016166-6F9A8BCB-B556-4F5C-9BEE-BA84C63BA00EQ38038106-5F1A10B8-771C-4F7E-9C00-24D03381E3C6Q38084359-335FC4F9-1B0F-4184-858C-873249E8FE00
P2860
Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.
@ast
Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.
@en
type
label
Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.
@ast
Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.
@en
prefLabel
Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.
@ast
Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.
@en
P2860
P356
P1476
Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.
@en
P2093
P2860
P2888
P304
P356
10.1007/BF03033242
P577
2006-10-01T00:00:00Z